Human Antibody Therapeutics for Viral Disease pp 155-183

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 317)

Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics

  • Scott K. Dessain
  • S. P. Adekar
  • J. D. Berry

Native human antibodies are defined as those that arise naturally as the result of the functioning of an intact human immune system. The utility of native antibodies for the treatment of human viral diseases has been established through experience with hyperimmune human globulins. Native antibodies, as a class, differ in some respects from those obtained by recombinant library methods (phage or transgenic mouse) and possess distinct properties that may make them ideal therapeutics for human viral diseases. Methods for cloning native human antibodies have been beset by technical problems, yet many antibodies specific for viral antigens have been cloned. In the present review, we discuss native human antibodies and ongoing improvements in cloning methods that should facilitate the creation of novel, potent antiviral therapeutics obtained from the native human antibody repertoire.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD (2002) Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 20:1640–1648PubMedCrossRefGoogle Scholar
  2. Ames RS, Tornetta MA, McMillan LJ, Kaiser KF, Holmes SD, Appelbaum E, Cusimano DM, Theisen TW, Gross MS, Jones CS, et al (1995) Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display library. J Immunol 154:6355–6364PubMedGoogle Scholar
  3. Andris JS, Ehrlich PH, Ostberg L, Capra JD (1992) Probing the human antibody repertoire to exogenous antigens. Characterization of the H and L chain V region gene segments from anti-hepatitis B virus antibodies. J Immunol 149:4053–4059PubMedGoogle Scholar
  4. Arakelov S, Gorny MK, Williams C, Riggin CH, Brady F, Collett MS, Zolla-Pazner S (1993) Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. J Infect Dis 168:580–585PubMedGoogle Scholar
  5. Arinbjarnarson S, Valdimarsson H (2002) Generation of heterohybridomas secreting human immunoglobulins; pokeweed mitogen prestimulation is highly effective but phytohemagglutinin drives most B cells into apoptosis. J Immunol Methods 259:139–148PubMedCrossRefGoogle Scholar
  6. Aujard Y, Fauroux B (2002) Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 96 [Suppl B]:S9–S14PubMedGoogle Scholar
  7. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW (1996) A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A 93:7843–7848PubMedCrossRefGoogle Scholar
  8. Bailey SM, Murnane JP (2006) Telomeres, chromosome instability and cancer. Nucleic Acids Res 34:2408–2417PubMedCrossRefGoogle Scholar
  9. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, de Kruif J, Dietzschold B, Rupprecht CE, Goudsmit J (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79:9062–9068PubMedCrossRefGoogle Scholar
  10. Banchereau J, Rousset F (1991) Growing human B lymphocytes in the CD40 system. Nature 353:678–679PubMedCrossRefGoogle Scholar
  11. Barbas CF 3rd (1993) Recent advances in phage display. Curr Opin Biotechnol 4:526–530PubMedCrossRefGoogle Scholar
  12. Bazin R, Lemieux R (1989) Increased proportion of B cell hybridomas secreting monoclonal antibodies of desired specificity in cultures containing macrophage-derived hybridoma growth factor (IL-6). J Immunol Methods 116:245–249PubMedCrossRefGoogle Scholar
  13. Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71:154–163PubMedCrossRefGoogle Scholar
  14. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553–557PubMedCrossRefGoogle Scholar
  15. Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:343–351PubMedCrossRefGoogle Scholar
  16. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414PubMedCrossRefGoogle Scholar
  17. Borrebaeck CA, Danielsson L, Moller SA (1987) Human monoclonal antibodies produced from L-leucine methyl ester-treated and in vitro immunized peripheral blood lymphocytes. Biochem Biophys Res Commun 148:941–946PubMedCrossRefGoogle Scholar
  18. Borrebaeck CA, Danielsson L, Moller SA (1988) Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes. Proc Natl Acad Sci USA 85:3995–3999PubMedCrossRefGoogle Scholar
  19. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB (2004) A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with cytomegalovirus retinitis. Antiviral Res 64:103–111PubMedGoogle Scholar
  20. Bradbury AR, Marks JD (2004) Antibodies from phage antibody libraries. J Immunol Methods 290:29–49PubMedCrossRefGoogle Scholar
  21. Brezinschek HP, Brezinschek RI, Lipsky PE (1995) Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol 155:190–202PubMedGoogle Scholar
  22. Broliden K, Tolfvenstam T, Norbeck O (2006) Clinical aspects of parvovirus B19 infection. J Intern Med 260:285–304PubMedCrossRefGoogle Scholar
  23. Bron D, Delforge A, Lagneaux L, De Martynoff G, Bosmans E, Van der Auwera P, Snoeck R, Burny A, Stryckmans P (1990) Production of human monoclonal IgG antibodies reacting with cytomegalovirus (CMV). J Immunol Methods 130:209–216PubMedCrossRefGoogle Scholar
  24. Brown NA, Miller G (1982) Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus. J Immunol 128:24–29PubMedGoogle Scholar
  25. Butler JL, Lane HC, Fauci AS (1983) Delineation of optimal conditions for producing mouse-human heterohybridomas from human peripheral blood B cells of immunized subjects. J Immunol 130:165–168PubMedGoogle Scholar
  26. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, Waters J, Kliem V, Muller R, Thomas HC, Manns MP (1996) Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 24:489–493PubMedCrossRefGoogle Scholar
  27. Carroll WL, Thielemans K, Dilley J, Levy R (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 89:61–72PubMedCrossRefGoogle Scholar
  28. Casadevall A, Pirofski LA (2005) The potential of antibody-mediated immunity in the defence against biological weapons. Expert Opin Biol Ther 5:1359–1372PubMedCrossRefGoogle Scholar
  29. Casadevall A, Dadachova E, Pirofski LA (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695–703PubMedCrossRefGoogle Scholar
  30. Casali P, Inghirami G, Nakamura M, Davies TF, Notkins AL (1986) Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV. Science 234:476–479PubMedCrossRefGoogle Scholar
  31. CDC (1984) Postexposure prophylaxis of hepatitis B. Morb Mortal Wkly Rep 33:285–290Google Scholar
  32. CDC (1985) Recommendations for protection against viral hepatitis. Morb Mortal Wkly Rep 34:313–324, 329–335Google Scholar
  33. CDC (1996) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 45:1–36Google Scholar
  34. CDC (1997a) MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch Ophthalmol 115:1528–1536Google Scholar
  35. CDC (1997b) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 99:93–99CrossRefGoogle Scholar
  36. CDC (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531–537CrossRefGoogle Scholar
  37. CDC (2006) A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 55:209–210Google Scholar
  38. Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU (1993) A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol 151:7005–7015PubMedGoogle Scholar
  39. Champion JM, Kean RB, Rupprecht CE, Notkins AL, Koprowski H, Dietzschold B, Hooper DC (2000) The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 235:81–90PubMedCrossRefGoogle Scholar
  40. Chiorazzi N, Wasserman RL, Kunkel HG (1982) Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas. J Exp Med 156:930–935PubMedCrossRefGoogle Scholar
  41. Cieplinski W, Reardon P, Testa MA (1983) Non-random human chromosome distribution in human-mouse myeloma somatic cell hybrids. Cytogenet Cell Genet 35:93–99PubMedCrossRefGoogle Scholar
  42. Cole SP, Campling BG, Louwman IH, Kozbor D, Roder JC (1984) A strategy for the production of human monoclonal antibodies reactive with lung tumor cell lines. Cancer Res 44:2750–2753PubMedGoogle Scholar
  43. Colucci G, Kohtz DS, Waksal SD (1986) Preparation and characterization of human monoclonal antibodies directed against the hepatitis B virus surface antigen. Liver 6:145–152PubMedCrossRefGoogle Scholar
  44. Cote RJ, Morrissey DM, Houghton AN, Beattie EJ Jr, Oettgen HF, Old LJ (1983) Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci USA 80:2026–2030PubMedCrossRefGoogle Scholar
  45. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921–1929PubMedGoogle Scholar
  46. Croce CM, Linnenbach A, Hall W, Steplewski Z, Koprowski H (1980) Production of human hybridomas secreting antibodies to measles virus. Nature 288:488–489PubMedCrossRefGoogle Scholar
  47. Darveau A, Chevrier MC, Neron S, Delage R, Lemieux R (1993) Efficient preparation of human monoclonal antibody-secreting heterohybridomas using peripheral B lymphocytes cultured in the CD40 system. J Immunol Methods 159:139–143PubMedCrossRefGoogle Scholar
  48. Daugherty PS, Olsen MJ, Iverson BL, Georgiou G (1999) Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng 12:613–621PubMedCrossRefGoogle Scholar
  49. de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J (2006) A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58:359–368CrossRefGoogle Scholar
  50. Desgranges C, Paire J, Pichoud C, Souche S, Frommel D, Trepo C (1987) High affinity human monoclonal antibodies directed against hepatitis B surface antigen. J Virol Methods 16:281–292PubMedCrossRefGoogle Scholar
  51. Dessain SK, Adekar SP, Stevens JB, Carpenter KA, Skorski ML, Barnoski BL, Goldsby RA, Weinberg RA (2004) High efficiency creation of human monoclonal antibody-producing hybridomas. J Immunol Methods 291:109–122PubMedCrossRefGoogle Scholar
  52. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr (2000) Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation—a compassionate use experience. Bone Marrow Transplant 25:161–165PubMedCrossRefGoogle Scholar
  53. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M (2004) Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 77:1203–1208PubMedCrossRefGoogle Scholar
  54. Dietzschold B, Gore M, Casali P, Ueki Y, Rupprecht CE, Notkins AL, Koprowski H (1990) Biological characterization of human monoclonal antibodies to rabies virus. J Virol 64:3087–3090PubMedGoogle Scholar
  55. Dorfman N, Dietzschold B, Kajiyama W, Fu ZF, Koprowski H, Notkins AL (1994) Development of human monoclonal antibodies to rabies. Hybridoma 13:397–402PubMedCrossRefGoogle Scholar
  56. Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC (1991) Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 51:1190–1196PubMedCrossRefGoogle Scholar
  57. Ebeling SB, Bos HM, Slater R, Overkamp WJ, Cuthbert AP, Newbold RF, Zdzienicka MZ, Aarden LA (1998) Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. Cancer Res 58:2863–2868PubMedGoogle Scholar
  58. Ehrlich PH, Moustafa ZA, Justice JC, Harfeldt KE, Kelley RL, Ostberg L (1992) Characterization of human monoclonal antibodies directed against hepatitis B surface antigen. Hum Antibodies Hybridomas 3:2–7PubMedGoogle Scholar
  59. Eid AJ, Brown RA, Patel R, Razonable RR (2006) Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 43:40–48PubMedCrossRefGoogle Scholar
  60. Emanuel D, Gold J, Colacino J, Lopez C, Hammerling U (1984) A human monoclonal antibody to cytomegalovirus (CMV). J Immunol 133:2202–2205PubMedGoogle Scholar
  61. Enssle K, Kurrle R, Kohler R, Muller H, Kanzy EJ, Hilfenhaus J, Seiler FR (1991) A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 10:547–556PubMedCrossRefGoogle Scholar
  62. Ephrussi B, Weiss MC (1969) Hybrid somatic cells. Sci Am 220:26–35PubMedCrossRefGoogle Scholar
  63. Ergaz Z, Ornoy A (2006) Parvovirus B19 in pregnancy. Reprod Toxicol 21:421–435PubMedCrossRefGoogle Scholar
  64. Faller G, Vollmers HP, Weiglein I, Marx A, Zink C, Pfaff M, Muller-Hermelink HK (1990) HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies. Br J Cancer 62:595–598PubMedGoogle Scholar
  65. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE (2005) Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749–1759PubMedCrossRefGoogle Scholar
  66. Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, Ferretti S, Iappelli M, Rossi M, Rivanera D, Lilli D, Mancini C, Attili A, Berloco P (2004) Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36:535–538PubMedCrossRefGoogle Scholar
  67. Fiore AE, Wasley A, Bell BP (2006) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55:1–23Google Scholar
  68. Foung S, Perkins S, Kafadar K, Gessner P, Zimmermann U (1990) Development of microfusion techniques to generate human hybridomas. J Immunol Methods 134:35–42PubMedCrossRefGoogle Scholar
  69. Foung SK, Perkins S, Raubitschek A, Larrick J, Lizak G, Fishwild D, Engleman EG, Grumet FC (1984) Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. J Immunol Methods 70:83–90PubMedCrossRefGoogle Scholar
  70. Foung SK, Perkins S, Koropchak C, Fishwild DM, Wittek AE, Engleman EG, Grumet FC, Arvin AM (1985) Human monoclonal antibodies neutralizing varicella-zoster virus. J Infect Dis 152:280–285PubMedGoogle Scholar
  71. Foung SK, Perkins S, Bradshaw P, Rowe J, Rabin LB, Reyes GR, Lennette ET (1989) Human monoclonal antibodies to human cytomegalovirus. J Infect Dis 159:436–443PubMedGoogle Scholar
  72. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667PubMedGoogle Scholar
  73. Gandhi MK, Khanna R (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4:725–738PubMedCrossRefGoogle Scholar
  74. Gebauer W, Lindl T (1990) Construction of human monoclonal antibodies against rabies NS-protein antigen by Epstein-Barr virus transformation. Arzneimittelforschung 40:718–722PubMedGoogle Scholar
  75. Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES (2000) Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant 14:586–591PubMedCrossRefGoogle Scholar
  76. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS (1998) Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213–222PubMedCrossRefGoogle Scholar
  77. Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey E (2000) Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 25:751–755PubMedCrossRefGoogle Scholar
  78. Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, Young NS, Zolla-Pazner S, Wolf H, Gorny MK, Modrow S (1999) Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 73:1974–1979PubMedGoogle Scholar
  79. Gish RG, McCashland T (2006) Hepatitis B in liver transplant recipients. Liver Transpl 12:S54–S64PubMedCrossRefGoogle Scholar
  80. Goldsmith JC, Eller N, Mikolajczyk M, Manischewitz J, Golding H, Scott DE (2004) Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sang 86:125–129PubMedCrossRefGoogle Scholar
  81. Gray F, Kenney JS, Dunne JF (1995) Secretion capture and report web: use of affinity derivatized agarose microdroplets for the selection of hybridoma cells. J Immunol Methods 182:155–163PubMedCrossRefGoogle Scholar
  82. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, et al (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13:3245–3260PubMedGoogle Scholar
  83. Grunow R, Jahn S, Porstmann T, Kiessig SS, Steinkellner H, Steindl F, Mattanovich D, Gurtler L, Deinhardt F, Katinger H, et al (1988) The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J Immunol Methods 106:257–265PubMedCrossRefGoogle Scholar
  84. Gustafsson B, Jondal M, Sundqvist VA (1991) SPAM-8, a mouse-human heteromyeloma fusion partner in the production of human monoclonal antibodies. Establishment of a human monoclonal antibody against cytomegalovirus. Hum Antibodies Hybridomas 2:26–32PubMedGoogle Scholar
  85. Hadlock KG, Rowe J, Perkins S, Bradshaw P, Song GY, Cheng C, Yang J, Gascon R, Halmos J, Rehman SM, McGrath MS, Foung SK (1997) Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J Virol 71:5828–5840PubMedGoogle Scholar
  86. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74:10407–10416PubMedCrossRefGoogle Scholar
  87. Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231–243PubMedCrossRefGoogle Scholar
  88. Harris JF, Koropatnick J, Pearson J (1990) Spontaneous and radiation-induced genetic instability of heteromyeloma hybridoma cells. Mol Biol Med 7:485–493PubMedGoogle Scholar
  89. Harris JF, Hawley RG, Hawley TS, Crawford-Sharpe GC (1992) Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J Immunol Methods 148:199–207PubMedCrossRefGoogle Scholar
  90. Hartmann G, Krieg AM (2000) Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164:944–953PubMedGoogle Scholar
  91. Heijtink R, Paulij W, van Bergen P, van Roosmalen M, Rohm D, Eichentopf B, Muchmore E, de Man R, Osterhaus A (1999) In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. J Gen Virol 80:1529–1535PubMedGoogle Scholar
  92. Heijtink RA, Kruining J, Weber YA, de Man RA, Schalm SW (1995) Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an “inhibition in solution” assay. Hepatology 22:1078–1083PubMedCrossRefGoogle Scholar
  93. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O’Toole T, Parker G, Perl T, Russell PK, Tonat K (1999) Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281:2127–2137PubMedCrossRefGoogle Scholar
  94. Hirano T (1998) Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16:249–284PubMedCrossRefGoogle Scholar
  95. Hoffmann P, Jimenez-Diaz M, Weckesser J, Bessler WG (1996) Murine bone marrow-derived macrophages constitute feeder cells for human B cell hybridomas. J Immunol Methods 196:85–91PubMedCrossRefGoogle Scholar
  96. Hollinger FB, Liang TJ (2001) Hepatitis B virus. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams and Wilkins, Philadelphia, pp 2971–3036Google Scholar
  97. Holt SE, Glinsky VV, Ivanova AB, Glinsky GV (1999) Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog 25:241–248PubMedCrossRefGoogle Scholar
  98. Hooper JW, Custer DM, Thompson E (2003) Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181–195PubMedCrossRefGoogle Scholar
  99. Ichimori Y, Sasano K, Itoh H, Hitotsumachi S, Kimura Y, Kaneko K, Kida M, Tsukamoto K (1985) Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen. Biochem Biophys Res Commun 129:26–33PubMedCrossRefGoogle Scholar
  100. Ichimori Y, Harada K, Hitotsumachi S, Tsukamoto K (1987) Establishment of hybridoma secreting human monoclonal antibody against hepatitis B virus surface antigen. Biochem Biophys Res Commun 142:805–812PubMedCrossRefGoogle Scholar
  101. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW (1989) Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1:406–410PubMedCrossRefGoogle Scholar
  102. Jessup CF, Baxendale H, Goldblatt D, Zola H (2000) Preparation of human-mouse heterohybridomas against an immunising antigen. J Immunol Methods 246:187–202PubMedCrossRefGoogle Scholar
  103. Kabir A, Alavian SM, Ahanchi N, Malekzadeh R (2006) Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res 36:265–271PubMedCrossRefGoogle Scholar
  104. Kalantarov GF, Rudchenko SA, Lobel L, Trakht I (2002) Development of a fusion partner cell line for efficient production of human monoclonal antibodies from peripheral blood lymphocytes. Hum Antibodies 11:85–96PubMedGoogle Scholar
  105. Kang AS, Jones TM, Burton DR (1991) Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc Natl Acad Sci U S A 88:11120–11123PubMedCrossRefGoogle Scholar
  106. Kanzaki Y, Onoue F, Sakurai H, Ide T (2003) Telomerase upregulates expression levels of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor in normal human fibroblasts. Biochem Biophys Res Commun 305:150–154PubMedCrossRefGoogle Scholar
  107. Karpas A, Dremucheva A, Czepulkowski BH (2001) A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci U S A 98:1799–1804PubMedCrossRefGoogle Scholar
  108. Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602–614PubMedCrossRefGoogle Scholar
  109. Kirman I, Kalantarov GF, Lobel LI, Hibshoosh H, Estabrook A, Canfield R, Trakht I (2002) Isolation of native human monoclonal autoantibodies to breast cancer. Hybrid Hybridomics 21:405–414PubMedCrossRefGoogle Scholar
  110. Kitamura K, Yamada K, Kuzushima K, Morishima T, Morishima Y, Yamamoto N, Nishiyama Y, Ohya K, Yamaguchi H (1990) Human monoclonal antibodies to human cytomegalovirus derived from peripheral blood lymphocytes of healthy adults. J Med Virol 32:60–66PubMedCrossRefGoogle Scholar
  111. Kocher AA, Bonaros N, Dunkler D, Ehrlich M, Schlechta B, Zweytick B, Grimm M, Zuckermann A, Wolner E, Laufer G (2003) Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 22:250–257PubMedCrossRefGoogle Scholar
  112. Koropatnick J, Pearson J, Harris JF (1988) Extensive loss of human DNA accompanies loss of antibody production in heteromyeloma hybridoma cells. Mol Biol Med 5:69–83PubMedGoogle Scholar
  113. Kozbor D, Roder JC, Chang TH, Steplewski Z, Koprowski H (1982) Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma. Hybridoma 1:323–328PubMedGoogle Scholar
  114. Kozbor D, Roder JC, Sierzega ME, Cole SP, Croce CM (1986) Comparative phenotypic analysis of available human hybridoma fusion partners. Methods Enzymol 121:120–140PubMedCrossRefGoogle Scholar
  115. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y (2002) In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations—a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 12:133–139PubMedCrossRefGoogle Scholar
  116. Krenn V, von Landenberg P, Wozniak E, Kissler C, Hermelink HK, Zimmermann U, Vollmers HP (1995) Efficient immortalization of rheumatoid synovial tissue B-lymphocytes. A comparison between the techniques of electric field-induced and PEG fusion. Hum Antibodies Hybridomas 6:47–51PubMedGoogle Scholar
  117. Lafon M, Edelman L, Bouvet JP, Lafage M, Montchatre E (1990) Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol 71:1689–1696PubMedCrossRefGoogle Scholar
  118. Lane JM, Ruben FL, Neff JM, Millar JD (1969) Complications of smallpox vaccination, 1968. N Engl J Med 281:1201–1208PubMedCrossRefGoogle Scholar
  119. Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D, Sallusto F (2006) Understanding and making use of human memory B cells. Immunol Rev 211:303–309PubMedCrossRefGoogle Scholar
  120. Larrick JW, Truitt KE, Raubitschek AA, Senyk G, Wang JC (1983) Characterization of human hybridomas secreting antibody to tetanus toxoid. Proc Natl Acad Sci U S A 80:6376–6380PubMedCrossRefGoogle Scholar
  121. Law M, Smith GL (2001) Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280:132–142PubMedCrossRefGoogle Scholar
  122. Lewis AP, Lemon SM, Barber KA, Murphy P, Parry NR, Peakman TC, Sims MJ, Worden J, Crowe JS (1993) Rescue, expression, and analysis of a neutralizing human anti-hepatitis A virus monoclonal antibody. J Immunol 151:2829–2838PubMedGoogle Scholar
  123. Lewis FM, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC (2006) Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis 12:134–137PubMedGoogle Scholar
  124. Lo KJ, Tsai YT, Lee SD, Wu TC, Wang JY, Chen GH, Yeh CL, Chiang BN, Yeh SH, Goudeau A, et al (1985) Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 152:817–822PubMedGoogle Scholar
  125. Love JC, Ronan JL, Grotenbreg GM, van der Veen AG, Ploegh HL (2006) A microengraving method for rapid selection of single cells producing antigen-specific antibodies. Nat Biotechnol 24:703–707PubMedCrossRefGoogle Scholar
  126. Meijer PJ, Andersen PS, Haahr Hansen M, Steinaa L, Jensen A, Lantto J, Oleksiewicz MB, Tengbjerg K, Poulsen TR, Coljee VW, Bregenholt S, Haurum JS, Nielsen LS (2006) Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J Mol Biol 358:764–772PubMedCrossRefGoogle Scholar
  127. Moudgil A, Shidban H, Nast CC, Bagga A, Aswad S, Graham SL, Mendez R, Jordan SC (1997) Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 64:1847–1850PubMedCrossRefGoogle Scholar
  128. Ohizumi Y, Suzuki H, Matsumoto Y, Masuho Y, Numazaki Y (1992) Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. J Gen Virol 73:2705–2707PubMedCrossRefGoogle Scholar
  129. Ohlin M, Borrebaeck CA (1996) Characteristics of human antibody repertoires following active immune responses in vivo. Mol Immunol 33:583–592PubMedCrossRefGoogle Scholar
  130. Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA (1993) Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 67:703–710PubMedGoogle Scholar
  131. Olsson L, Kronstrom H, Cambon-De Mouzon A, Honsik C, Brodin T, Jakobsen B (1983) Antibody producing human-human hybridomas. I. Technical aspects. J Immunol Methods 61:17–32PubMedCrossRefGoogle Scholar
  132. Oral HB, Ozakin C, Akdis CA (2002) Back to the future: antibody-based strategies for the treatment of infectious diseases. Mol Biotechnol 21:225–239PubMedCrossRefGoogle Scholar
  133. Oshimura M, Barrett JC (1997) Multiple pathways to cellular senescence: role of telomerase repressors. Eur J Cancer 33:710–715PubMedCrossRefGoogle Scholar
  134. Panova I, Gustafsson B (1995) Increased human hybridoma formation by electrofusion of human B cells with heteromyeloma SPAM-8 cells. Hybridoma 14:265–269PubMedCrossRefGoogle Scholar
  135. Pavoni E, Monteriu G, Cianfriglia M, Minenkova O (2006) New display vector reduces biological bias for expression of antibodies in E. coli. Gene 391:120–129PubMedCrossRefGoogle Scholar
  136. Pereira-Smith OM, Robetorye S, Ning Y, Orson FM (1990) Hybrids from fusion of normal human T lymphocytes with immortal human cells exhibit limited life span. J Cell Physiol 144:546–549PubMedCrossRefGoogle Scholar
  137. Perkins S, Zimmermann U, Foung SK (1991) Parameters to enhance human hybridoma formation with hypoosmolar electrofusion. Hum Antibodies Hybridomas 2:155–159PubMedGoogle Scholar
  138. Posner MR, Elboim H, Santos D (1987) The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 6:611–625PubMedCrossRefGoogle Scholar
  139. Potera C (2005) Filling the niche for effective MAb screening. Genet Eng News 25Google Scholar
  140. Pratt M, Mikhalev A, Glassy MC (1987) The generation of Ig-secreting UC 729–6 derived human hybridomas by electrofusion. Hybridoma 6:469–477PubMedCrossRefGoogle Scholar
  141. Ramirez JC, Tapia E, Esteban M (2002) Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol 83:1059–1067PubMedGoogle Scholar
  142. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS (1987) Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316:673–676PubMedCrossRefGoogle Scholar
  143. Redmond MJ, Leyritz-Wills M, Winger L, Scraba DG (1986) The selection and characterization of human monoclonal antibodies to human cytomegalovirus. J Virol Methods 14:9–24PubMedCrossRefGoogle Scholar
  144. Rioux JD, Larose Y, Brodeur BR, Radzioch D, Newkirk MM (1994) Structural characteristics of four human hybridoma antibodies specific for the pp65 protein of the human cytomegalovirus and their relationship to human rheumatoid factors. Mol Immunol 31:585–597PubMedCrossRefGoogle Scholar
  145. Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA (1997) Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 99:454–461PubMedCrossRefGoogle Scholar
  146. Ruttmann E, Geltner C, Bucher B, Ulmer H, Hofer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Muller LC (2006) Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81:1415–1420PubMedCrossRefGoogle Scholar
  147. Sa’adu A, Locniskar M, Bidwell D, Howard C, McAdam KP, Voller A (1992) Development and characterization of human anti-HBs antibodies. J Virol Methods 36:25–34PubMedCrossRefGoogle Scholar
  148. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293:1155–1159PubMedCrossRefGoogle Scholar
  149. Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47:57–77PubMedCrossRefGoogle Scholar
  150. Schlom J, Wunderlich D, Teramoto YA (1980) Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci U S A 77: 6841–6845PubMedCrossRefGoogle Scholar
  151. Schmidt E, Leinfelder U, Gessner P, Zillikens D, Brocker EB, Zimmermann U (2001) CD19+ B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. J Immunol Methods 255:93–102PubMedCrossRefGoogle Scholar
  152. Sechet A, Bridoux F, Bauwens M, Ayache RA, Belmouaz S, Touchard G (2002) Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins. Transplant Proc 34:812–813PubMedCrossRefGoogle Scholar
  153. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ (2001) Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 183:16–22PubMedCrossRefGoogle Scholar
  154. Shirahata S, Katakura Y, Teruya K (1998) Cell hybridization, hybridomas, and human hybridomas. Methods Cell Biol 57:111–145PubMedCrossRefGoogle Scholar
  155. Shulman M, Wilde CD, Kohler G (1978) A better cell line for making hybridomas secreting specific antibodies. Nature 276:269–270PubMedCrossRefGoogle Scholar
  156. Siemoneit K, da Silva Cardoso M, Wolpl A, Koerner K, Subanek B (1994) Isolation and epitope characterization of human monoclonal antibodies to hepatitis C virus core antigen. Hybridoma 13:9–13PubMedCrossRefGoogle Scholar
  157. Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, Ushay HM, Sepkowitz KA (2002) Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 29:321–327PubMedCrossRefGoogle Scholar
  158. Smith GL, Vanderplasschen A, Law M (2002) The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83:2915–2931PubMedGoogle Scholar
  159. Smith LL, Coller HA, Roberts JM (2003) Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 5:474–479PubMedCrossRefGoogle Scholar
  160. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL Jr, Levey AS, et al (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317:1049–1054PubMedCrossRefGoogle Scholar
  161. Sokos DR, Berger M, Lazarus HM (2002) Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8:117–130PubMedCrossRefGoogle Scholar
  162. Stein LD, Sigal NH (1983) Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production. Cell Immunol 79:309–319PubMedCrossRefGoogle Scholar
  163. Stewart SA, Hahn WC, O’Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA (2002) Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99:12606–12611PubMedCrossRefGoogle Scholar
  164. Stricker EA, Tiebout RF, Lelie PN, Zeijlemaker WP (1985) A human monoclonal IgG1 lambda anti-hepatitis B surface antibody. Production, properties, and applications. Scand J Immunol 22:337–343PubMedCrossRefGoogle Scholar
  165. Sugano T, Matsumoto Y, Miyamoto C, Masuho Y (1987) Hybridomas producing human monoclonal antibodies against varicella-zoster virus. Eur J Immunol 17:359–364PubMedCrossRefGoogle Scholar
  166. Sugano T, Tomiyama T, Matsumoto Y, Sasaki S, Kimura T, Forghani B, Masuho Y (1991) A human monoclonal antibody against varicella-zoster virus glycoprotein III. J Gen Virol 72:2065–2073PubMedCrossRefGoogle Scholar
  167. Tan MP, Koren G (2006) Chickenpox in pregnancy: revisited. Reprod Toxicol 21:410–420PubMedCrossRefGoogle Scholar
  168. Terrault NA, Vyas G (2003) Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 7:537–550PubMedCrossRefGoogle Scholar
  169. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL (1998) Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28:555–561PubMedCrossRefGoogle Scholar
  170. Thompson JM, Lowe J, McDonald DF (1994) Human monoclonal anti-D secreting heterohybridomas from peripheral B lymphocytes expanded in the CD40 system. J Immunol Methods 175:137–140PubMedCrossRefGoogle Scholar
  171. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179–186PubMedCrossRefGoogle Scholar
  172. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE Jr (2007) Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory B cells. Mol Immunol 44:2173–2183PubMedCrossRefGoogle Scholar
  173. Tiebout RF, van Boxtel-Oosterhof F, Stricker EA, Zeijlemaker WP (1987) A human hybrid hybridoma. J Immunol 139:3402–3405PubMedGoogle Scholar
  174. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875PubMedCrossRefGoogle Scholar
  175. Ueki Y, Goldfarb IS, Harindranath N, Gore M, Koprowski H, Notkins AL, Casali P (1990) Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 171:19–34PubMedCrossRefGoogle Scholar
  176. Vaisbourd M, Ignatovich O, Dremucheva A, Karpas A, Winter G (2001) Molecular characterization of human monoclonal antibodies derived from fusions of tonsil lymphocytes with a human myeloma cell line. Hybrid Hybridomics 20:287–292PubMedCrossRefGoogle Scholar
  177. Varga M, Remport A, Hidvegi M, Peter A, Kobori L, Telkes G, Fazakas J, Gerlei Z, Sarvary E, Sulyok B, Jaray J (2005) Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience. Transpl Infect Dis 7:63–67PubMedCrossRefGoogle Scholar
  178. Welliver RC (2003) Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 22: S6–S10; discussion S10–S12PubMedCrossRefGoogle Scholar
  179. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433–455PubMedCrossRefGoogle Scholar
  180. Xiao XM, Li AZ, Chen X, Zhu YK, Miao J (2007) Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet 96:167–170PubMedCrossRefGoogle Scholar
  181. Xu JL, Davis MM (2000) Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13:37–45PubMedCrossRefGoogle Scholar
  182. Xu Q, Xiao L, Lu XB, Zhang YX, Cai X (2006) A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol 12:3434–3437PubMedGoogle Scholar
  183. Yoshinari K, Arai K, Kimura H, Matsumoto K, Yamaguchi Y (1996) Efficient production of IgG human monoclonal antibodies by lymphocytes stimulated by lipopolysaccharide, pokeweed mitogen, and interleukin 4. In Vitro Cell Dev Biol Anim 32:372–377PubMedCrossRefGoogle Scholar
  184. Young J (2002) Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 96 [Suppl B]:S31–35PubMedGoogle Scholar
  185. Zhu Y, Jin B, Sun C, Huang C, Liu X (1993) The effects of hybridoma growth factor in conditioned media upon the growth, cloning, and antibody production of heterohybridoma cell lines. Hum Antibodies Hybridomas 4:31–35PubMedGoogle Scholar
  186. Zhu Y, Jin B, Jiang S, Sun K, Sun C, Liu X (1999) Improved fusion partners transfected with DNA fragment encoding IL-11 on generation of human B lymphocyte hybridomas. Hum Antibodies 9:1–7PubMedGoogle Scholar
  187. Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A (1998) A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83:132–137PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Scott K. Dessain
    • 1
  • S. P. Adekar
    • 1
  • J. D. Berry
    • 2
  1. 1.Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Monoclonal Antibody and Bioforensic Development SectionsNational Microbiology LaboratoryWinnipegCanada

Personalised recommendations